Oncolytics Biotech is trading at $0.57, down 5.14%, amid biotech-sector weakness; no clear catalyst for the decline was identified.
- An October 8 search found no fresh company-specific announcement explaining the decline; recent coverage concerned earlier research findings.
- XBI was down 2.04% in regular trading, with no clear sector-wide catalyst identified.
- No volume or activity-level data was available in the supplied price context or search results.